Merck KGaA buys out gene therapy specialist Mirus Bio for $600M – FiercePharma

MilliporeSigma, the Massachusetts-based contract manufacturing arm of Merck KGaA, is increasing its presence in the gene therapy manufacturing field as it has signed an agreement to acquire Mirus Bio for $600 million.

The 19-year-old company being acquired, which is based in Madison, Wisconsin, is a subsidiary of Gamma Biosciences. It develops and commercializes transfection reagents, which allow genetic material to be incorporated into cells and play a pivotal role in the production of viral vector-based gene therapies.

Back to news